COVID-19 导致的血管内皮损伤：补体、HIF-1 和 ABL2 是损伤的潜在途径和治疗靶点。
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.
机构信息
Hematology Department, Az Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
出版信息
Ann Hematol. 2020 Aug;99(8):1701-1707. doi: 10.1007/s00277-020-04138-8. Epub 2020 Jun 24.
Abstract
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.
摘要
COVID-19 大流行是一场重大的卫生紧急事件，在全球范围内造成数百人死亡。高发病率与缺氧和炎症有关，导致小血管和大血管的内皮功能障碍和异常凝血。这篇综述探讨了导致内皮紊乱的一些途径，如补体、HIF-1α 和 ABL 酪氨酸激酶。这篇综述还强调了预防和治疗 COVID-19 相关器官损伤的潜在靶点，并讨论了上市药物（如依库珠单抗和伊马替尼）作为临床试验合适候选药物的作用。
相似文献
1
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.COVID-19 导致的血管内皮损伤：补体、HIF-1 和 ABL2 是损伤的潜在途径和治疗靶点。
Ann Hematol. 2020 Aug;99(8):1701-1707. doi: 10.1007/s00277-020-04138-8. Epub 2020 Jun 24.
2
COVID-19 May Predispose to Thrombosis by Affecting Both Vascular Endothelium and Platelets.新冠病毒可能通过影响血管内皮和血小板而导致血栓形成。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620933945. doi: 10.1177/1076029620933945.
3
Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis.高血糖水平通过 HIF-1α/糖酵解依赖轴促进 SARS-CoV-2 感染和单核细胞反应。
Cell Metab. 2020 Sep 1;32(3):437-446.e5. doi: 10.1016/j.cmet.2020.07.007. Epub 2020 Jul 17.
4
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.COVID-19 患者的激肽释放酶-激肽系统阻断治疗以预防急性呼吸窘迫综合征。
Elife. 2020 Apr 27;9:e57555. doi: 10.7554/eLife.57555.
5
Imatinib for COVID-19: A case report.伊马替尼治疗新型冠状病毒肺炎：一例病例报告。
Clin Immunol. 2020 Sep;218:108518. doi: 10.1016/j.clim.2020.108518. Epub 2020 Jun 27.
6
Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.使用多梳蛋白抑制剂作为抗病毒药物靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）
Epigenomics. 2020 May;12(10):811-812. doi: 10.2217/epi-2020-0154. Epub 2020 Jun 4.
7
COVID-19 and the endothelium.COVID-19 与血管内皮。
Clin Hemorheol Microcirc. 2020;75(1):7-11. doi: 10.3233/CH-209007.
8
Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19.新型冠状病毒肺炎重症患者的内皮糖萼损伤
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1178-1181. doi: 10.1164/rccm.202007-2676LE.
9
The complement inhibitors in COVID-19: future expectations.新冠病毒肺炎中的补体抑制剂：未来展望
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6480-6481. doi: 10.26355/eurrev_202006_21628.
10
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.
引用本文的文献
1
COVID-19: a vascular nightmare unfolding.新冠病毒肺炎：一场正在展现的血管噩梦。
Front Immunol. 2025 Aug 1;16:1593885. doi: 10.3389/fimmu.2025.1593885. eCollection 2025.
2
Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.利用免疫治疗分子和诊断生物标志物作为人源佐剂用于中东呼吸综合征冠状病毒疫苗开发。
Front Immunol. 2025 Mar 13;16:1538301. doi: 10.3389/fimmu.2025.1538301. eCollection 2025.
3
A KSHV-targeted small molecule efficiently blocks SARS-CoV-2 infection via inhibiting expression of EGFR and Cyclin A2.一种靶向卡波西肉瘤相关疱疹病毒的小分子通过抑制表皮生长因子受体（EGFR）和细胞周期蛋白A2（Cyclin A2）的表达有效阻断严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Emerg Microbes Infect. 2025 Dec;14(1):2440490. doi: 10.1080/22221751.2024.2440490. Epub 2024 Dec 19.
4
Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome? : A critical review.高压氧疗法在新冠后遗症患者中的应用是否合理？：一项批判性综述。
Eur Arch Psychiatry Clin Neurosci. 2024 Dec;274(8):1797-1817. doi: 10.1007/s00406-024-01911-y. Epub 2024 Nov 15.
5
Genetic and epigenetic regulation of cortactin (CTTN) by inflammatory factors and mechanical stress in human lung endothelial cells.炎症因子和机械应激对人肺内皮细胞中皮层肌动蛋白（CTTN）的遗传和表观遗传调控
Biosci Rep. 2024 Sep 25;44(9). doi: 10.1042/BSR20231934.
6
The mechanistic basis linking cytokine storm to thrombosis in COVID-19.将细胞因子风暴与COVID-19中的血栓形成联系起来的机制基础。
Thromb Update. 2022 Aug;8:100110. doi: 10.1016/j.tru.2022.100110. Epub 2022 May 18.
7
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.精准营养以重置长期新冠病毒感染中病毒诱导的人类代谢重编程和失调（HMRD）。
NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2.
8
Exploring COVID-19 causal genes through disease-specific Cis-eQTLs.通过疾病特异性顺式-eQTLs 探索 COVID-19 因果基因。
Virus Res. 2024 Apr;342:199341. doi: 10.1016/j.virusres.2024.199341. Epub 2024 Feb 25.
9
Comprehensive Assessment of Eyes in Kidney Transplant Recipients after Recovering from COVID-19.新冠病毒感染康复后肾移植受者眼部综合评估
Life (Basel). 2023 Sep 30;13(10):2003. doi: 10.3390/life13102003.
10
How the immune response to the structural proteins of SARS-CoV-2 affects the retinal vascular endothelial cells: an immune thrombotic and/or endotheliopathy process with in silico modeling.新冠病毒结构蛋白引起的免疫反应如何影响视网膜血管内皮细胞：一种免疫血栓形成和/或内皮病变过程的计算机模拟研究。
Immunol Res. 2024 Feb;72(1):50-71. doi: 10.1007/s12026-023-09412-1. Epub 2023 Aug 29.
本文引用的文献
1
Hematological findings in coronavirus disease 2019: indications of progression of disease.2019 年冠状病毒病的血液学表现：疾病进展的迹象。
Ann Hematol. 2020 Jul;99(7):1421-1428. doi: 10.1007/s00277-020-04103-5. Epub 2020 Jun 3.
2
Epidemiology and clinical features of COVID-19: A review of current literature.新型冠状病毒肺炎的流行病学和临床特征：文献复习。
J Clin Virol. 2020 Jun;127:104357. doi: 10.1016/j.jcv.2020.104357. Epub 2020 Apr 10.
3
Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.新型冠状病毒感染患者的凝血功能障碍：COVID-19、SARS-CoV-1、MERS-CoV 及过去的经验教训。
J Clin Virol. 2020 Jun;127:104362. doi: 10.1016/j.jcv.2020.104362. Epub 2020 Apr 9.
4
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
5
Mechanism of thrombocytopenia in COVID-19 patients.新型冠状病毒肺炎患者血小板减少的机制。
Ann Hematol. 2020 Jun;99(6):1205-1208. doi: 10.1007/s00277-020-04019-0. Epub 2020 Apr 15.
6
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.严重新型冠状病毒肺炎与非新型冠状病毒肺炎患者凝血功能特征的差异。
J Thromb Thrombolysis. 2021 May;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.
7
Hypoxia-induced complement dysregulation is associated with microvascular impairments in mouse tracheal transplants.缺氧诱导的补体失调与小鼠气管移植中的微血管损伤有关。
J Transl Med. 2020 Mar 31;18(1):147. doi: 10.1186/s12967-020-02305-z.
8
NADPH oxidase-mediated endothelial injury in HIV- and opioid-induced pulmonary arterial hypertension.NADPH 氧化酶介导致血管内皮损伤在 HIV 和阿片类药物引起的肺动脉高压中的作用。
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1097-L1108. doi: 10.1152/ajplung.00480.2019. Epub 2020 Apr 1.
9
Mitochondrial superoxide mediates PM-induced cytotoxicity in human pulmonary lymphatic endothelial cells.线粒体超氧阴离子介导 PM 诱导的人肺淋巴管内皮细胞细胞毒性。
Environ Pollut. 2020 Aug;263(Pt A):114423. doi: 10.1016/j.envpol.2020.114423. Epub 2020 Mar 21.
10
Sirolimus and propranolol inhibit endothelial proliferation while detergent sclerosants induce endothelial activation, microparticle release and apoptosis in vitro.西罗莫司和普萘洛尔抑制内皮细胞增殖，而去污剂硬化剂在体外诱导内皮细胞激活、微颗粒释放和细胞凋亡。
Phlebology. 2020 Sep;35(8):566-575. doi: 10.1177/0268355520913384. Epub 2020 Mar 26.
Zotero 插件